NCT01506700

Brief Summary

This is a single-arm, prospective, study of an optical imaging device on approximately twenty (20) subjects undergoing lumpectomies at one study site. In vivo and ex vivo imaging will be performed on study subjects with results being compared to final pathology.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 6, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 10, 2012

Completed
4 months until next milestone

Study Start

First participant enrolled

May 1, 2012

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2013

Completed
5.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 17, 2019

Completed
Last Updated

July 26, 2019

Status Verified

July 1, 2019

Enrollment Period

1.6 years

First QC Date

January 6, 2012

Last Update Submit

July 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • The sensitivity and specificity of Optical Coherence Tomography to identify whether or not tumor can be identified ex vivo on breast cancer specimens as compared to post-surgical histology conclusions.

    One week after surgery

Interventions

Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Females with breast cancer

You may qualify if:

  • Women 18 years of age or older
  • Signed ICF
  • Women who have been histologically diagnosed with invasive ductal carcinoma or invasive lobular carcinoma of the breast prior to surgery
  • Planning breast preservation
  • Patients undergoing lumpectomy (partial mastectomy) procedure

You may not qualify if:

  • Multicentric disease (histologically diagnosed cancer in two different quadrants of the breast)
  • Neoadjuvant systemic therapy
  • All T4 tumors
  • Previous radiation in the operated breast
  • Prior surgical procedure in the same quadrant
  • Implants in the operated breast
  • Pregnancy
  • Lactation
  • Participating in any other investigational study for either drug or device which can influence collection of valid data under this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carle Foundation Hospital

Urbana, Illinois, 61801, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Tomography, Optical Coherence

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Tomography, OpticalOptical ImagingDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisTomographyInvestigative Techniques

Study Officials

  • Stephen A Boppart, MD, PhD

    University of Illinois and Diagnostic Photonics, Inc.

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 6, 2012

First Posted

January 10, 2012

Study Start

May 1, 2012

Primary Completion

December 20, 2013

Study Completion

July 17, 2019

Last Updated

July 26, 2019

Record last verified: 2019-07

Locations